PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27822709-11	2017	CONCLUSIONS: ITPA polymorphism influences hemoglobin levels and incidence of RBV dose reduction during sofosbuvir plus RBV therapy.	Sofosbuvir	103-113	inosine triphosphatase	Homo sapiens	13-17	
28128521-0	2017	ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin.	Sofosbuvir	110-120	inosine triphosphatase	Homo sapiens	0-4	
28109022-0	2017	Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.	Sofosbuvir	136-146	inosine triphosphatase	Homo sapiens	40-62	
27822709-0	2017	ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection.	Sofosbuvir	59-69	inosine triphosphatase	Homo sapiens	0-4	
27822709-0	2017	ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. BACKGROUND: Polymorphisms in the inosine triphosphatase (ITPA) gene is associated with anemia induced by peg-interferon (PEG-IFN) plus ribavirin (RBV) treatment for patients with chronic hepatitis C virus (HCV) infection.	Sofosbuvir	59-69	inosine triphosphatase	Homo sapiens	164-186